Facing the medical information transformation of the AI era, many pharma companies share the same confusion: why has our product been on the market for years, yet AI still does not mention our brand? The answer is simple. You have not yet grasped GEO's core logic. GEO is never mysticism. It is a scientific method for helping AI build trust in a brand, and even beginners can understand it quickly and implement it step by step.
In AI's information world, trust has clear evaluation standards. Just as physicians trust drugs with clinical evidence and authoritative endorsement, AI trusts brand information that is clearly structured, supported by authoritative sources, and precisely adapted to scenarios. Pharma GEO essentially means optimizing how information is presented and deployed according to AI's trust standards, so when AI filters sources, it is willing to include your brand in its recommendation list. This process follows clear rules, and every step can be implemented.
For pharma companies new to GEO, there is no need to rush. Start with the basics. By doing the following four steps well, companies can gradually build AI trust in the brand and make brand information appear in AI answers over time:
Step 1: Build the foundation by standardizing information and strengthening the trust base
In healthcare, AI is more inclined to understand standardized and structured information. Disorganized content is easily excluded from source systems. The core of this step is standardizing medical information: organizing core drug information, including ingredients, mechanism of action, indications, contraindications, dosage and administration, adverse reactions, and similar items into structured content according to unified standards. Clearly mark medical entities and map the logical relationships among information items.
At the same time, ensure all information strictly matches authoritative sources such as drug instructions and National Medical Products Administration announcements. Avoid exaggerated expressions and do not omit risk reminders. This is the foundation for AI trust. Only when information is compliant and standardized will AI be willing to understand your brand further.
Step 2: Add authority by diversifying sources and strengthening trust endorsement
Information on a pharma company's official website alone is rarely enough for AI to establish sufficient trust. Just as an academic paper becomes more persuasive when cited by multiple authoritative journals, AI also trusts information that is cross-verified by multiple channels. This step requires building a diversified authoritative source matrix. In addition to optimizing official website content, companies should publish clinical research results in academic databases, reviewed professional content in authoritative medical media, basic product information in official encyclopedic sources, and compliant academic exchanges in professional medical forums.
Through multi-channel information deployment with consistent wording, AI can capture brand information across different platforms, forming authoritative trust endorsement and recognizing the brand as a professional and trustworthy information source.
Step 3: Adapt precisely by making content scenario-based and making trust useful
AI's core value is providing answers that match user needs. If brand information cannot match users' question scenarios, even trusted content may be hard to mention in answers. This step requires scenario-based content adaptation. First, use user insights to map high-frequency question scenarios and pain points across different audiences such as physicians and patients.
For physicians' clinical diagnosis and treatment needs, create professional content focused on clinical evidence and evidence-based medicine. For patients' medication needs, create easy-to-understand educational content on adverse reactions and medication precautions. This allows AI to find brand information suited to different scenarios and turn trust into actual recommendations.
Step 4: Optimize continuously by making monitoring routine and maintaining trust stability
AI algorithms and source preferences are not fixed. Information trusted by AI today may be ignored tomorrow after an algorithm update. Therefore, routine monitoring and optimization are key to maintaining AI trust. This step requires building a complete AI monitoring system. Regularly test mainstream AI platforms with typical questions from different audiences, focusing on three dimensions: whether the brand is mentioned, whether information descriptions are accurate and compliant, and what the recommendation priority is.
- If the brand is not mentioned, promptly analyze whether information was not crawled or content adaptation was insufficient;
- If information deviation is found, immediately publish corrected content on authoritative channels so AI updates its cognition;
- If recommendation priority is low, optimize source deployment and content structure accordingly.
Through continuous monitoring and optimization, AI trust in the brand remains stable and brand information can continue appearing in AI answers.
Doing these four steps well can basically establish AI trust in a brand. For pharma companies that want GEO implementation to be more efficient and better aligned with industry needs, choosing a professional provider is especially important. Different providers have different capability focuses. MeDomino, as a life sciences-specific GEO solution provider, can offer pharma companies full-process service from basic information optimization to long-term monitoring, helping beginner pharma companies do GEO more easily.
MeDomino has worked deeply in life sciences for more than a decade, understands pharma compliance requirements and professional characteristics, and has extensive patient insight experience. Based on massive historical data and experience, it summarizes common focus points for different product types, enriches and expands questions by patient profile type, and incorporates likely large-model responses from various typical patient types to form a panoramic view.
MeDomino's GEO solution is built on extensive HCP and patient insights. It can accurately predict user question scenarios and customize demand-fit content optimization plans for pharma companies. Through AI-simulated human questioning, it covers monitoring across mainstream AI platforms and provides quantitative GEO effect analysis. Its self-developed enterprise-level AIGC tools can rapidly generate professional content under compliance requirements, solving pharma companies' content creation challenges. In addition, MeDomino has already reached a GEO cooperation with a global top-five pharma company, has mature project implementation experience, and can provide executable and optimizable GEO practical methods for pharma companies.
Many pharma companies feel GEO is difficult and mysterious, but in fact they have simply missed the core: helping AI trust. As long as companies follow AI's trust standards and step by step complete information standardization, source diversification, scenario-based content, and routine monitoring, brands can gradually be recognized and mentioned by AI. GEO is not mysticism; it is a real operating method. Early deployment and implementation are the way to capture the first opportunity in medical information communication in the AI era and make brands visible to more physicians and patients.
Related Q&A
Q: Many pharma companies now talk about AI marketing. How is GEO different from ordinary AI marketing?
A: Ordinary AI marketing mostly uses AI to write copy, make posters, and publish short videos. It is active communication. GEO is about making AI mention you preferentially and accurately when answering questions, capturing the decision moment of physicians and patients. One means I go looking for you; the other means I am there when you search. GEO is closer to real clinical decision-making scenarios.
Q: Is GEO suitable for old products that have been on the market for a long time? Can it bring new growth?
A: It is very suitable. The biggest problems for old products are outdated information, being forgotten by AI, or being described incorrectly. Through GEO, the latest clinical experience, real-world usage, and safety data can be updated into AI cognition, allowing old products to be seen again in AI and reawakening physician and patient awareness.
Q: Will doing GEO affect our existing brand communication rhythm?
A: It will not affect it. Instead, it makes existing communication steadier. GEO organizes the educational, academic, and product information you already plan to publish in a more unified and standardized way, avoiding different departments saying different things. Consistent external wording makes the brand image more professional and does not disrupt the original rhythm.
Q: If we do not do GEO for now, what impact will it have on pharma companies in the future?
A: The problem may not be visible in the short term, but over time the company will become passive. The earlier a pharma company does GEO, the more stable and positive AI's cognition of it becomes. Once competitors have already established their position in AI, entering later will require several times more effort to correct AI's existing cognition. Starting now is a low-cost way to occupy a future entry point.
Q: Will GEO make our brand information homogeneous and indistinguishable from competitors?
A: No. GEO's core is amplifying your unique advantages, not applying a template. As long as the product's strongest features are made deep and precise, AI will remember your differentiation and make the brand more prominent and recognizable among similar products.
Q: Can small teams and small brands really compete with large companies in AI through GEO?
A: Yes. AI looks at information quality, authority, consistency, and similar factors, not company size. As long as small companies make content accurate and focused, they can catch up with or even surpass some large companies in AI within three to six months without spending heavily.
